Literature DB >> 20685286

Chemical-specific screening criteria for interpretation of biomonitoring data for volatile organic compounds (VOCs)--application of steady-state PBPK model solutions.

Lesa L Aylward1, Chris R Kirman, Ben C Blount, Sean M Hays.   

Abstract

The National Health and Nutrition Examination Survey (NHANES) generates population-representative biomonitoring data for many chemicals including volatile organic compounds (VOCs) in blood. However, no health or risk-based screening values are available to evaluate these data from a health safety perspective or to use in prioritizing among chemicals for possible risk management actions. We gathered existing risk assessment-based chronic exposure reference values such as reference doses (RfDs), reference concentrations (RfCs), tolerable daily intakes (TDIs), cancer slope factors, etc. and key pharmacokinetic model parameters for 47 VOCs. Using steady-state solutions to a generic physiologically-based pharmacokinetic (PBPK) model structure, we estimated chemical-specific steady-state venous blood concentrations across chemicals associated with unit oral and inhalation exposure rates and with chronic exposure at the identified exposure reference values. The geometric means of the slopes relating modeled steady-state blood concentrations to steady-state exposure to a unit oral dose or unit inhalation concentration among 38 compounds with available pharmacokinetic parameters were 12.0 microg/L per mg/kg-d (geometric standard deviation [GSD] of 3.2) and 3.2 microg/L per mg/m(3) (GSD=1.7), respectively. Chemical-specific blood concentration screening values based on non-cancer reference values for both oral and inhalation exposure range from 0.0005 to 100 microg/L; blood concentrations associated with cancer risk-specific doses at the 1E-05 risk level ranged from 5E-06 to 6E-02 microg/L. The distribution of modeled steady-state blood concentrations associated with unit exposure levels across VOCs may provide a basis for estimating blood concentration screening values for VOCs that lack chemical-specific pharmacokinetic data. The screening blood concentrations presented here provide a tool for risk assessment-based evaluation of population biomonitoring data for VOCs and are most appropriately applied to central tendency estimates for such datasets. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20685286     DOI: 10.1016/j.yrtph.2010.05.011

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  6 in total

1.  Human health risk assessment and PAHs in a stretch of river Ganges near Kanpur.

Authors:  Pooja Srivastava; T R Sreekrishnan; A K Nema
Journal:  Environ Monit Assess       Date:  2017-08-10       Impact factor: 2.513

Review 2.  Breath volatile organic compounds for the gut-fatty liver axis: promise, peril, and path forward.

Authors:  Steven Francis Solga
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

3.  Evaluation of biomonitoring data from the CDC National Exposure Report in a risk assessment context: perspectives across chemicals.

Authors:  Lesa L Aylward; Christopher R Kirman; Rita Schoeny; Christopher J Portier; Sean M Hays
Journal:  Environ Health Perspect       Date:  2012-12-11       Impact factor: 9.031

4.  Application of physiologically based pharmacokinetic models in chemical risk assessment.

Authors:  Moiz Mumtaz; Jeffrey Fisher; Benjamin Blount; Patricia Ruiz
Journal:  J Toxicol       Date:  2012-03-19

5.  Development of screening tools for the interpretation of chemical biomonitoring data.

Authors:  Richard A Becker; Sean M Hays; Steven Robison; Lesa L Aylward
Journal:  J Toxicol       Date:  2012-02-16

6.  A Physiologically-Based Pharmacokinetic Modeling Approach Using Biomonitoring Data in Order to Assess the Contribution of Drinking Water for the Achievement of an Optimal Fluoride Dose for Dental Health in Children.

Authors:  Keven J Jean; Nancy Wassef; Fabien Gagnon; Mathieu Valcke
Journal:  Int J Environ Res Public Health       Date:  2018-06-28       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.